163 related articles for article (PubMed ID: 38580878)
21. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma.
McKeever PE; Strawderman MS; Yamini B; Mikhail AA; Blaivas M
J Neuropathol Exp Neurol; 1998 Oct; 57(10):931-6. PubMed ID: 9786243
[TBL] [Abstract][Full Text] [Related]
22. Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index.
Yan R; Haopeng P; Xiaoyuan F; Jinsong W; Jiawen Z; Chengjun Y; Tianming Q; Ji X; Mao S; Yueyue D; Yong Z; Jianfeng L; Zhenwei Y
Neuroradiology; 2016 Feb; 58(2):121-32. PubMed ID: 26494463
[TBL] [Abstract][Full Text] [Related]
23. Proliferative activity as measured by MIB-1 labeling index and long-term outcome of visual pathway astrocytomas in children.
Czech T; Slavc I; Aichholzer M; Haberler C; Dietrich W; Dieckmann K; Koos W; Budka H
J Neurooncol; 1999 Apr; 42(2):143-50. PubMed ID: 10421072
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
[TBL] [Abstract][Full Text] [Related]
25. Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index.
Uehara K; Sasayama T; Miyawaki D; Nishimura H; Yoshida K; Okamoto Y; Mukumoto N; Akasaka H; Nishihara M; Fujii O; Soejima T; Sugimura K; Kohmura E; Sasaki R
Radiat Oncol; 2012 Jun; 7():104. PubMed ID: 22734595
[TBL] [Abstract][Full Text] [Related]
26. Estimation of proliferative potentiality of central neurocytoma: correlational analysis of minimum ADC and maximum SUV with MIB-1 labeling index.
Sakamoto R; Okada T; Kanagaki M; Yamamoto A; Fushimi Y; Kakigi T; Arakawa Y; Takahashi JC; Mikami Y; Togashi K
Acta Radiol; 2015 Jan; 56(1):114-20. PubMed ID: 24477268
[TBL] [Abstract][Full Text] [Related]
27. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas.
Hsu DW; Louis DN; Efird JT; Hedley-Whyte ET
J Neuropathol Exp Neurol; 1997 Aug; 56(8):857-65. PubMed ID: 9258255
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.
Wakimoto H; Aoyagi M; Nakayama T; Nagashima G; Yamamoto S; Tamaki M; Hirakawa K
Cancer; 1996 Jan; 77(2):373-80. PubMed ID: 8625247
[TBL] [Abstract][Full Text] [Related]
29. Prognostic marker analysis in pediatric intracranial ependymomas.
McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
[TBL] [Abstract][Full Text] [Related]
30. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.
Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C
Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.
Kros JM; Hop WC; Godschalk JJ; Krishnadath KK
Cancer; 1996 Sep; 78(5):1107-13. PubMed ID: 8780550
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of histological features in diffuse astrocytomas WHO grade II.
Lind-Landström T; Habberstad AH; Sundstrøm S; Torp SH
Int J Clin Exp Pathol; 2012; 5(2):152-8. PubMed ID: 22400076
[TBL] [Abstract][Full Text] [Related]
33. Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.
Nitta M; Muragaki Y; Maruyama T; Ikuta S; Komori T; Maebayashi K; Iseki H; Tamura M; Saito T; Okamoto S; Chernov M; Hayashi M; Okada Y
Neurosurg Focus; 2015 Jan; 38(1):E7. PubMed ID: 25599276
[TBL] [Abstract][Full Text] [Related]
34. Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression.
Widhalm G; Wolfsberger S; Preusser M; Fischer I; Woehrer A; Wunderer J; Hainfellner JA; Knosp E
J Neurosurg; 2009 Sep; 111(3):563-71. PubMed ID: 18991501
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas.
Stanton KJ; Sidner RA; Miller GA; Cummings OW; Schmidt CM; Howard TJ; Wiebke EA
Am J Surg; 2003 Nov; 186(5):486-92. PubMed ID: 14599612
[TBL] [Abstract][Full Text] [Related]
36. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
37. A topographic analysis of the proliferating tumor cells in an autopsied brain with infiltrative thalamic glioma.
Amin MR; Kamitani H; Watanabe T; Ishibashi M; Ogawa T; Funakoshi T; Miyata H; Ohama E
Brain Tumor Pathol; 2002; 19(1):5-10. PubMed ID: 12455882
[TBL] [Abstract][Full Text] [Related]
38. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas.
Hsu DW; Efird JT; Hedley-Whyte ET
Neuropathol Appl Neurobiol; 1998 Dec; 24(6):441-52. PubMed ID: 9888154
[TBL] [Abstract][Full Text] [Related]
39. The correlation between 99mTc-MIBI uptake and MIB-1 as a nuclear proliferation marker in glioma--a comparative study with 201Tl.
Nagamachi S; Jinnouchi S; Nabeshima K; Nishii R; Flores L; Kodama T; Kawai K; Tamura S; Yokogami K; Samejima T; Wakisaka S
Neuroradiology; 2001 Dec; 43(12):1023-30. PubMed ID: 11792039
[TBL] [Abstract][Full Text] [Related]
40. Cellular proliferation in pilocytic and diffuse astrocytomas.
Giannini C; Scheithauer BW; Burger PC; Christensen MR; Wollan PC; Sebo TJ; Forsyth PA; Hayostek CJ
J Neuropathol Exp Neurol; 1999 Jan; 58(1):46-53. PubMed ID: 10068313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
